Anders Jorsal

List of Publications by Year
in descending order

29 papers	1,688 citations	471509 17 h-index	477307 29 g-index
29 all docs	29 docs citations	29 times ranked	3143 citing authors

#	Article	IF	Citations
1	Visit‐to‐visit variability of clinical risk markers in relation to long‐term complications in type 1 diabetes. Diabetic Medicine, 2021, 38, e14459.	2.3	7
2	Optimizing heart failure treatment following cardiac resynchronization therapy. Clinical Research in Cardiology, 2020, 109, 638-645.	3.3	12
3	Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. European Heart Journal, 2020, 41, 328-328.	2.2	12
4	The impact of the glucagon‐like peptide‐1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2141-2150.	4.4	16
5	Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events. Scandinavian Cardiovascular Journal, 2020, 54, 294-299.	1.2	10
6	Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. Diabetes Care, 2019, 42, 1512-1520.	8.6	77
7	Quantitative estimation of extravascular lung water volume and preload by dynamic 15O-water positron emission tomography. European Heart Journal Cardiovascular Imaging, 2019, 20, 1120-1128.	1.2	9
8	Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study. Journal of Nuclear Cardiology, 2019, 26, 585-597.	2.1	18
9	Heart Failure. Endocrinology and Metabolism Clinics of North America, 2018, 47, 117-135.	3.2	17
10	Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism. Journal of Nuclear Cardiology, 2018, 25, 169-176.	2.1	32
11	Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study. Diabetes, 2017, 66, 2278-2283.	0.6	63
12	Effect of long-term remote ischemic conditioning in patients with chronic ischemic heart failure. Basic Research in Cardiology, 2017, 112, 67.	5.9	45
13	Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. Kidney International, 2017, 92, 1242-1248.	5.2	24
14	Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (<scp>LIVE</scp>)â€"a multicentre, double‐blind, randomised, placebo‐controlled trial. European Journal of Heart Failure, 2017, 19, 69-77.	7.1	343
15	High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 1603-1608.	2.3	6
16	IGFBP-4 Fragments as Markers of Cardiovascular Mortality in Type 1 Diabetes Patients With and Without Nephropathy. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3032-3040.	3.6	32
17	A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE) Tj ETQq1 1 0.784314 rgBT /Over		
18	Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes. Journal of Diabetes and Its Complications, 2013, 27, 604-608.	2.3	16

#	Article	IF	Citations
19	Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes. Diabetes Care, 2011, 34, 442-447.	8.6	202
20	Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy. Diabetes Care, 2010, 33, 1567-1572.	8.6	98
21	Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes. Diabetes, 2010, 59, 2027-2032.	0.6	109
22	Soluble CD40 ligand is elevated in Type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets, 2010, 21, 525-532.	2.3	30
23	A Single Nucleotide Polymorphism within the Acetyl-Coenzyme A Carboxylase Beta Gene Is Associated with Proteinuria in Patients with Type 2 Diabetes. PLoS Genetics, 2010, 6, e1000842.	3.5	81
24	Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. Nephrology Dialysis Transplantation, 2009, 24, 3343-3349.	0.7	11
25	The endothelial nitric oxide synthase gene and risk of diabetic nephropathy and development of cardiovascular disease in type 1 diabetes. Molecular Genetics and Metabolism, 2009, 97, 80-84.	1.1	37
26	Plasma Concentration of Asymmetric Dimethylarginine (ADMA) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy. Diabetes Care, 2008, 31, 747-752.	8.6	121
27	Plasma Connective Tissue Growth Factor Is an Independent Predictor of End-Stage Renal Disease and Mortality in Type 1 Diabetic Nephropathy. Diabetes Care, 2008, 31, 1177-1182.	8.6	99
28	Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney International, 2008, 74, 649-654.	5.2	124
29	Polymorphisms in the B-type natriuretic peptide (BNP) gene are associated with NT-proBNP levels but not with diabetic nephropathy or mortality in type 1 diabetic patients. Nephrology Dialysis Transplantation, 2007, 22, 3235-3239.	0.7	15